title: New drugs in gynecologic cancer.
abstract: The implementation of new drug treatments has improved the prognosis for advanced cancers of the cervix, uterus, and ovary. Platinum analogs are the most effective drugs in the treatment of ovarian cancer. Other drugs, such as oxaliplatin, have been proposed as a rational treatment of platinum refractory ovarian cancer. Epothilones are also being studied in clinical trials, as are histone deacetylase inhibitors. Several promising agents may soon receive Food and Drug Administration approval.
authors.affiliation: Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
authors.forename: A
authors.initials: A
authors.lastname: Daud
authors.forename: P
authors.initials: P
authors.lastname: Munster
authors.forename: P
authors.initials: P
authors.lastname: Munster
authors.forename: D R
authors.initials: DR
authors.lastname: Spriggs
mesh_terms: D000631:Aminopyridines / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D002945:Cisplatin / Q000031:analogs & derivatives; D005260:Female; D000077156:Gefitinib; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D047029:Lactams, Macrocyclic; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011719:Pyrazines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D000631:Aminopyridines; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001897:Boronic Acids; D006877:Hydroxamic Acids; D047029:Lactams, Macrocyclic; D009944:Organoplatinum Compounds; D011719:Pyrazines; D011799:Quinazolines; C110525:amminedichloro(2-methylpyridine)platinum(II); C428024:pyroxamide; D000069286:Bortezomib; D011505:Protein-Tyrosine Kinases; C114062:BBR 3464; D000068878:Trastuzumab; D017239:Paclitaxel; D002945:Cisplatin; D000077156:Gefitinib